I now have comprehensive material from Harrison's and Rosen's. Let me compile the full answer.
Hyperglycemia - Definition, Causes & Pathophysiology
Definition
Hyperglycemia refers to an abnormally elevated blood glucose concentration. It is the shared phenotype of all forms of diabetes mellitus (DM) and the central metabolic derangement from which downstream complications arise. Diagnostically, the thresholds are:
| Test | Normal | Prediabetes (Impaired) | Diabetes |
|---|
| Fasting plasma glucose (FPG) | < 100 mg/dL (5.6 mmol/L) | 100-125 mg/dL (5.6-6.9 mmol/L) | ≥ 126 mg/dL (7.0 mmol/L) |
| 2-h post-OGTT glucose | < 140 mg/dL | 140-199 mg/dL | ≥ 200 mg/dL (11.1 mmol/L) |
| HbA1c | < 5.7% | 5.7-6.4% | ≥ 6.5% |
| Random glucose + symptoms | - | - | ≥ 200 mg/dL |
DM is formally defined as the level of glycemia at which diabetes-specific complications (e.g., retinopathy) occur - not merely a statistical deviation from a population mean. - Harrison's Principles of Internal Medicine 22E
Normal Glucose Homeostasis (Context for Pathophysiology)
Maintaining normal plasma glucose requires precise matching of glucose use, endogenous glucose production, and dietary intake. Five key hormones regulate this balance:
- Insulin (from pancreatic beta cells) - the primary glucose-lowering hormone. It suppresses hepatic glucose production, stimulates GLUT4-mediated glucose uptake in muscle and fat, promotes glycogen synthesis, lipogenesis, and protein synthesis via the PI3-kinase - IRS signaling cascade. About 50% of secreted insulin is cleared by the liver on first pass.
- Glucagon (alpha cells) - released in response to hypoglycemia, stress, trauma, infection, exercise, and starvation. Rapidly increases hepatic glycogenolysis and gluconeogenesis.
- Epinephrine / Norepinephrine - stimulate hepatic glucose production and limit peripheral glucose uptake via alpha- and beta-adrenergic mechanisms.
- Cortisol - increases hepatic gluconeogenesis and inhibits skeletal muscle glucose uptake. Major contributor to stress hyperglycemia.
- Growth hormone - antagonizes insulin action.
When any of these counterregulatory hormones are elevated, or when insulin secretion or action is impaired, hyperglycemia results. - Rosen's Emergency Medicine
Causes of Hyperglycemia
1. Type 1 Diabetes Mellitus
Autoimmune destruction of pancreatic beta cells leads to absolute insulin deficiency. The process is driven by genetic susceptibility (HLA associations), environmental triggers, and islet-directed autoimmunity (autoantibodies against islet cell antigens, GAD, IA-2, ZnT8). Beta cell mass declines progressively over years (Stage 1: autoantibodies, normoglycemia → Stage 2: dysglycemia → Stage 3: overt diabetes/DKA). Without insulin, glucose cannot enter muscle or fat cells, hepatic glucose output goes unchecked, and ketogenesis occurs.
2. Type 2 Diabetes Mellitus
A heterogeneous group of disorders involving:
- Insulin resistance - peripheral tissues (muscle, fat, liver) respond poorly to insulin. The PI3-kinase / GLUT4 axis is impaired. This is the first detectable defect, heralded by postprandial hyperinsulinemia, then fasting hyperinsulinemia.
- Impaired insulin secretion - progressive beta cell dysfunction fails to compensate for insulin resistance. Relative insulin deficiency ensues.
- Increased hepatic glucose production - gluconeogenesis and glycogenolysis are inadequately suppressed.
In T2DM, decreased insulin sensitivity also prevents suppression of lipolysis in adipose tissue, raising circulating free fatty acids, which further worsen insulin resistance. - Harrison's and Creasy & Resnik's Maternal-Fetal Medicine
3. Other Specific Causes (Secondary Hyperglycemia)
| Category | Examples |
|---|
| Endocrinopathies | Cushing's syndrome (excess cortisol), acromegaly (excess GH), pheochromocytoma (excess catecholamines), glucagonoma, hyperthyroidism |
| Pancreatic disease | Chronic pancreatitis, cystic fibrosis, hemochromatosis, pancreatectomy - islet destruction from exocrine pathology |
| Monogenic diabetes (MODY) | Single-gene defects in beta cell function (HNF-1α, glucokinase, HNF-4α, etc.) - autosomal dominant, early onset |
| Drugs/medications | Glucocorticoids, antipsychotics (atypical), tacrolimus/cyclosporine, thiazide diuretics, protease inhibitors, some chemotherapy agents |
| Stress hyperglycemia | Surgery, critical illness, sepsis - surge of counterregulatory hormones (cortisol, catecholamines, glucagon) overrides insulin action, even in non-diabetic patients |
| Insulin receptor defects | Severe insulin resistance syndromes (mutations in the insulin receptor gene) |
| Mitochondrial mutations | Mitochondrial DNA defects impair beta cell energy metabolism |
| Gestational diabetes | Placental hormones (hPL, progesterone, cortisol) produce physiological insulin resistance exceeding secretory reserve |
Pathophysiologic Mechanisms at the Cellular Level
In insulin deficiency or resistance:
- Reduced GLUT4 translocation - skeletal muscle and adipose tissue cannot take up glucose.
- Unrestrained hepatic glucose output - both glycogenolysis and gluconeogenesis proceed without inhibition.
- Lipolysis - insulin normally suppresses hormone-sensitive lipase; without it, free fatty acids flood the circulation, serving as gluconeogenic substrates and further impairing insulin signaling (lipotoxicity).
- Glucotoxicity - chronic hyperglycemia itself impairs beta cell function (glucose toxicity), creating a self-perpetuating cycle.
Downstream effects of sustained hyperglycemia (leading to complications):
- Increased reactive oxygen species (ROS)
- Activation of the polyol pathway (glucose → sorbitol → fructose), depleting NADPH
- PKC activation via de novo synthesis of diacylglycerol
- Hexosamine pathway alterations
- Non-enzymatic glycation - formation of advanced glycosylation end products (AGEs)
These pathways collectively underlie the microvascular and macrovascular complications of diabetes. - Goldman-Cecil Medicine / Brenner and Rector's The Kidney
Glucose Threshold and Osmotic Effects
When plasma glucose exceeds the renal tubular reabsorption threshold (~180 mg/dL for SGLT2 transporters), glucosuria occurs. This creates an osmotic diuresis - water follows glucose into the urine, resulting in:
- Polyuria
- Polydipsia (compensatory)
- Dehydration and weight loss
- In severe cases: hypotension, vascular collapse
Early manifestations of hyperglycemia include weakness, polyuria, polydipsia, altered vision, and mild dehydration. Prolonged severe hyperglycemia with metabolic acidosis manifests as Kussmaul breathing, stupor, coma, hypotension, and cardiac arrhythmias. - Medical Physiology (Boron & Boulpaep)
Sources: Harrison's Principles of Internal Medicine 22E | Medical Physiology (Boron & Boulpaep) | Rosen's Emergency Medicine | Goldman-Cecil Medicine | Brenner and Rector's The Kidney | Creasy & Resnik's Maternal-Fetal Medicine